Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Rheumatology

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3899/jrheum.150479PMID 26523026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current and future prospects in the management of granulomatosis with polyangiitis (Wegener’s granulomatosis)

  2014cited by this paper
• Key advances in the clinical approach to ANCA-associated vasculitis

  2014cited by this paper
• Granulomatosis With Polyangiitis (Wegener’s)

  2014cited by this paper
• BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.

  2014cited by this paper
• Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides

  2013cited by this paper
• 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

  2013cited by this paper
• Granulomatosis with Polyangiitis (Wegener's)

  2012cited by this paper
• Treatment of antineutrophil cytoplasmic antibody-associated vasculitis

  2012cited by this paper
• Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades.

  2011cited by this paper
• Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

  2010cited by this paper
• Long-term patient survival in ANCA-associated vasculitis

  2010cited by this paper
• Epidemiological features of Wegener's granulomatosis and microscopic polyangiitis: two diseases or one ‘anti‐neutrophil cytoplasm antibodies‐associated vasculitis’ entity?

  2009cited by this paper
• Health-related quality of life for patients with vasculitis and their spouses.

  2009cited by this paper
• Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

  2008cited by this paper
• BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

  2007cited by this paper
• Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review.

  2007cited by this paper
• Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis

  2005cited by this paper
• Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.

  2003cited by this paper
• Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis.

  2003cited by this paper
• Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis.

  2002cited by this paper
• A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

  2001cited by this paper
• Self-assessed physical and mental function of haemodialysis patients.

  2001cited by this paper
• The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.

  1996cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

  1992cited by this paper

• Comparing incidence of vasculitis between farming, rural and urban population: A population-based study.

  2026cites this paper
• Drivers of hospital costs in ANCA-associated vasculitis patients with long-term follow-up—a real-world cost analysis

  2025cites this paper
• Recaída en pacientes con vasculitis asociadas a ANCA: un estudio de cohorte en un centro de enfermedades reumatológicas en Colombia

  2024cites this paper
• Relapse in patients with ANCA-associated vasculitis: A cohort study from a centre for rheumatic diseases in Colombia

  2024cites this paper
• Hydroxychloroquine as a potential therapy for ANCA-associated vasculitis

  2024cites this paper
• Disease Overlap, Healthcare Resource Utilization, and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A REVEAL Sub-study

  2024cites this paper
• Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States.

  2024cites this paper
• The HAVEN study—hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan

  2023cites this paper
• Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis

  2023cites this paper
• Epidemiology and treatment outcome of ANCA-associated vasculitis in South Korea: a nationwide, population-based cohort study.

  2023influential citation
• Antineutrophil cytoplasmic antibody-associated vasculitis with predominant truncal muscle weakness: a retrospective case series

  2023cites this paper
• Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and the Risk of Developing Incidental Tuberculosis: A Population-Based Cohort Study

  2023cites this paper
• Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States

  2023cites this paper
• Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study

  2023influential citation
• Retrospective Analysis of the Burden of Illness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Versus Asthma in Commercially Insured US Patients

  2023influential citation
• Health care costs and utilization prior to diagnosis of antineutrophil cytoplasmic antibody vasculitis in Medicare beneficiaries

  2022cites this paper
• An adapted passive model of anti-MPO dependent crescentic glomerulonephritis reveals matrix dysregulation and is amenable to modulation by CXCR4 inhibition.

  2022cites this paper
• Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States

  2021cites this paper
• New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study.

  2021cites this paper
• Epidemiology and genetics of granulomatosis with polyangiitis

  2021cites this paper
• The Many Faces of Vasculitis: Diagnostic Challenges and Economic Burden

  2021cites this paper
• Cellular Adhesion Is a Controlling Factor in Neutrophil Extracellular Trap Formation Induced by Anti-Neutrophil Cytoplasmic Antibodies

  2021cites this paper
• Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases

  2020cites this paper
• Die wirtschaftliche Belastung durch ANCA-assoziierte Vaskulitiden in Deutschland – eine Versorgungsdatenstudie

  2020cites this paper
• Causes of hypereosinophilia in 100 consecutive patients.

  2020cites this paper
• ANCA-associated vasculitis

  2020cites this paper
• The Delay and Costs of Diagnosing Systemic Vasculitis in a Tertiary-Level Clinic

  2020cites this paper
• Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.

  2019cites this paper
• Real-world evidence in rheumatic diseases: relevance and lessons learnt

  2019cites this paper
• Economic and objective burden of caregiving on informal caregivers of patients with systemic vasculitis.

  2019cites this paper
• Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis.

  2019cites this paper
• Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

  2018cites this paper
• Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States

  2018cites this paper
• Post-transplantation Presentation of ANCA-associated Vasculitis: Granulomatosis with Polyangitis

  2018cites this paper
• Epidemiology and Outcomes of Granulomatosis With Polyangiitis in Pediatric and Working‐Age Adult Populations In the United States

  2018cites this paper
• Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis.

  2018influential citation
• Incremental Costs in Giant Cell Arteritis

  2018cites this paper
• Examining whether the information–motivation–behavioral skills model predicts medication adherence for patients with a rare disease

  2017cites this paper
• Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon‐based to direct‐acting antivirals era

  2017cites this paper
• Update on systemic vasculitides

  2017cites this paper
• Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases

  2017cites this paper
• Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon‐based to direct‐acting antivirals era

  2017cites this paper
• Development and validation of case‐finding algorithms for the identification of patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis in large healthcare administrative databases

  2016cites this paper